

1 Prognostic implications of Global Longitudinal Strain versus Ejection 2 Fraction in End-stage Renal Disease: a systematic review protocol

3 Barbara Leticia da Silva Guedes de Moura¹. blguedes@gmail.com
4 Anderson Gusthavo dos Santos Muceniekis¹. anderson.g.muceniekis@gmail.com
5 Enrico Prajante Bertolino¹. enricopbertolino@gmail.com
6 Giordanna Chiqueto Duarte¹. ra109863@uem.br
7 João Vitor Dudek. Inga University Center, PR². joaovdudek@gmail.com
8 Mariana Amâncio Daniel da Silva¹. marianamanciodanielsiva@gmail.com
9 Izabel Galhardo Demarchi³. i.g.demarchi@ufsc.br
10 Sergio Seiji Yamada¹. sergioyamada62@gmail.com
11 Rogerio Toshiro Passos Okawa¹. rogerokawa@uol.com.br
12 Jorge Juarez Vieira Teixeira¹. jjvteixeira@gmail.com

13
14 Institutional addresses:

15 ¹State University of Maringa: Universidade Estadual de Maringa, Maringa – PR/BR. Av.
16 Colombo, 5790, Jd Universitario. CEP: 87.020-900\CCS. + 55 44 3011 4890.

17 ²Uningá, Inga University Center: Rod. PR 317, 6114 Parque Industrial 200, Maringá -
18 PR, CEP: 87.035-510. +55 44 30 33 5009.

19 ³Federal University of Santa Catarina (UFSC): Universidade Federal de Santa Catarina
20 - CCS - Departamento de Análises Clínicas Campus Universitário – Trindade. CEP:
21 88.040-970 - Florianópolis – SC. Fone: +55 48 3721 4159.

22 Corresponding Author:

23 Ms Barbara Leticia da Silva Guedes de Moura

24 blguedes@gmail.com

25 +55 44 9 9928 1401

26 ABSTRACT

27 **Background:** In hemodialysis (HD) patients, the presence of Heart failure (HF) at the
28 start of dialysis is a strong and independent predictor of short and long-term mortality,
29 and its prevalence increases with declining kidney function and HD time. Left ventricular
30 (LV) ejection fraction (EF) is widely used as a measure of systolic function. Reduced EF
31 (<50%) is an important prognostic marker, however, less than 15% of End-stage Renal
32 Disease (ESRD) patients have detectable systolic dysfunction and the EF is susceptible
33 to loading conditions, which change dramatically during interdialytic intervals. Global
34 Longitudinal Strain (GLS) derived by 2D Speckle-Tracking Echocardiography (STE) is
35 an emerging technique for measuring more subtle disturbances in LV systolic function.
36 Although ESRD patients have subclinical evidence of impaired strain but preserved EF,
37 there is evidence that GLS is better in ESRD group receiving maintenance HD compared
38 with moderate-advanced CKD patients. This systematic review will evaluate the
39 evidence related to the incremental prognostic value of LV GLS by 2D-STE concerning
40 mortality and cardiovascular (CV) events in ESRD patients. **Methods:** This protocol is
41 reported according to the PRISMA-P guideline. The databases PubMed, EMBASE,
42 LILACS, Web of Science, and Google Scholar system will be searched and double
43 screening for longitudinal studies that assessed the prospective association of STE-
44 derived parameters with at least one of the pre-specified outcomes in ESRD patients.
45 Discrepancies will be resolved through consensus. A modified version of the Newcastle-
46 Ottawa Quality Assessment Scale of cohort studies will be used. We intend to use the
47 random-effects model, considering at least moderate heterogeneity between studies. If
48 data allow, we will perform meta-regression to explore potential sources of between-
49 study heterogeneity. An adaptation of the GRADE framework for prognostic studies will
50 be employed to judge the quality of evidence for each outcome reported in this

51 **Systematic review.** **Discussion:** This systematic review will summarize current evidence

52 about STE-derived measures in the ESRD patients and clarify the incremental prognostic
53 value of this diagnostic tool versus LVEF in these patients. Evidence about other
54 measures (circumferential and radial strain) or 3D STE-derived indices will also be
55 investigated.

56 **Systematic review registration**

57 This systematic review protocol was submitted to the PROSPERO international registry
58 of systematic reviews (Registration number: CRD42020222505).

59 **Keywords**

60 End-Stage Renal Disease; global longitudinal strain; prognosis; speckle tracking
61 echocardiography.

62

63 **Strengths and limitations of this study**

64 → The PROSPERO registry helps to promote and maintain transparency in the process
65 and to assist in minimizing the risk of bias. Four databases and one additional grey
66 literature source helps ensure more complete coverage of the topic. A modified version
67 of the Newcastle-Ottawa Quality Assessment Scale of cohort studies will be used and
68 an adaptation of the GRADE framework for prognostic studies to assess the quality of
69 evidence for each outcome reported will be applied. All the review phases will be peer-
70 reviewed and will be validated by methodological and clinical experts.

71 →Left ventricular (LV) ejection fraction (EF) is widely used as a measure of systolic
72 function. Reduced EF (50%) is an important prognostic marker, however, less than 15%
73 of End-Stage Renal Disease (ESRD) patients have detectable systolic dysfunction.
74 Global Longitudinal Strain (GLS) derived by 2D Speckle-Tracking Echocardiography
75 (STE) is an emerging technique for measuring more subtle disturbances in LV systolic
76 function, however, its incremental prognostic value to ESRD is controversial.

77 → This study has limitations. Because heterogeneity is quite common in these
78 systematic reviews, there may be limited scope for meta-analysis. Possibly, the spectrum
79 of patients in different research sites is the main factor, in most cases, but heterogeneity
80 in associations between studies may be difficult to explain.

81 →This systematic review will evaluate the evidence related to the GLS incremental
82 prognostic value in End-Stage Renal Disease patients, which may lower morbidity and
83 mortality and influence its use as a prognostic marker for ESRD patients.

84

85 **Background**

86 Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in
87 patients with advanced chronic kidney disease (CKD), accounting for >50% of all
88 deaths.[1] Although classical Framingham risk factors remain important, there is
89 increasing evidence to support renal-specific and dialytic disturbances increases the
90 cardiovascular risk in this population, such as sodium/fluid balance, hyperuricemia,
91 inflammation, vascular calcification, and abnormal bone mineral metabolism [2], and this
92 complex interaction results in a high prevalence of abnormalities of cardiac structure and
93 function in patients with End-stage Renal Disease (ESRD) [3].

94 Though hemodialysis (HD) should theoretically improve cardiovascular function
95 by correcting fluid overload and small molecule accumulation, cardiovascular mortality
96 continues to be disproportionately high in the HD population [4]. The impact of renal
97 replacement therapy (RRT) on cardiovascular function and injury is not well understood
98 and may inadvertently be contributing to the accelerated development of type 4
99 cardiorenal syndrome (CRS): CKD leading to an impairment of cardiac function. The
100 unique physiology of cardiovascular abnormalities in dialysis patients remains poorly
101 understood and several more recently recognized factors, including altered lipid
102 metabolism and accumulation of gut microbiota-derived uremic toxins, also affect
103 cardiovascular function in the context of renal failure [5].

104 Left ventricular (LV) ejection fraction (EF) is widely used as a measure of systolic
105 function. Reduced EF (<50%) is an important prognostic marker, however, less than 15%
106 of ESRD patients have detectable systolic dysfunction [6] and the prognostic ability of
107 EF can be limited because it is susceptible to loading conditions [7], which change
108 dramatically during interdialytic intervals in hemodialysis patients [8].

109 Global Longitudinal Strain (GLS) derived by Two-dimensional (2D) Speckle-
110 Tracking Echocardiography (STE) is an emerging technique for measuring more subtle
111 disturbances in LV systolic function. There is emerging data that GLS is a superior

112 predictor of cardiac events and all-cause mortality compared with EF in the general
113 population with and without heart failure (HF) [9,10] even among HF patients with
114 preserved LVEF [11]. Impaired GLS was proved to be associated with microvascular
115 ischemia, interstitial fibrosis, and cardiac myocyte hypertrophy caused by urotoxin,
116 hypertension, and hemodialysis-related myocardial stunning [12-14] which would all lead
117 to cardiovascular mortality and morbidity.

118 Although studies have demonstrated that patients with moderate-to-severe CKD
119 and dialysis patients have subclinical evidence of impaired strain but preserved EF
120 [14,15] there is evidence that GLS is better in ESRD group receiving maintenance HD
121 compared with moderate-advanced CKD patients [16]. Dialysis patients are susceptible
122 to dramatic changes in loading conditions during interdialytic intervals [8]. Loading
123 conditions may be affect not only EF but also strain values [17] and although GLS
124 independently predicted the outcome in dialysis patients, it did not show incremental
125 prognostic value over the EF on the model with AROii score (a validated 2-year mortality
126 risk score in the hemodialysis cohort) [18].

127 The prognostic value of LV-GLS in the general CKD patients was demonstrated
128 in recent a meta-analysis [19], but considering the insufficient data until the research
129 date, they did not further analyze GLS in different stages of CKD, especially in ESRD
130 patients.

131 As the mechanism and applications of abnormal GLS in HD patients have not
132 been fully clarified, we will perform a systematic review of LV GLS as a predictor of total
133 and cardiovascular mortality and morbidity in the ESRD population specifically.

134 **Methods/Design**

135 This protocol is reported according to the Preferred Reporting Items for
136 Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) [20] and the
137 corresponding checklist used (Supplementary file 1). This includes details of inclusion
138 and exclusion criteria, a data extraction tool, and analytical methods. This systematic
139 review protocol was submitted to the PROSPERO international registry of systematic
140 reviews (Registration number: CRD42020222505).

141 Search strategy

142 The databases PubMed, EMBASE, LILACS (Latin American and Caribbean
143 Literature in Health Sciences), Web of Science, and Google Scholar system (grey
144 literature) and reference lists of eligible studies will be searched for publications until the
145 search date. The Search strategy were determined independently by three authors
146 (BLSGM, RTPO, and JJVT) and were developed first for the PubMed database and the
147 effectiveness will be tested and refined accordingly. The search strategy was developed
148 using two combined blocks of keywords/subject headings (MeSH terms/PubMed) with
149 the Boolean operators OR/AND: (a) Block 1 – “global longitudinal strain” OR “speckle
150 tracking echocardiography”, (b) Block 2 – “chronic kidney disease” OR [‘haemodialysis’
151 OR ‘renal dialysis’ OR ‘renal AND dialysis’ OR ‘renal dialysis’ OR ‘hemodialysis’] OR
152 “end-stage renal disease”], (c) (a) AND (b). A detailed draft for the search strategy to be
153 used is detailed in Supplementary file 2. The search will be limited to original research
154 reports in peer-reviewed journals and only full-texts, with no language and publication
155 date restriction, will be retained.

156 Eligibility criteria

157 All longitudinal studies that assessed the prospective association of STE-derived
158 parameters with: (a) at least one of the pre-specified outcomes in ESRD (>18 years)
159 population, (b) following ethical standards, will be included and (c) Abstracts, reviews,
160 news, editorials, report cases, conference proceedings or letters to the editor will be
161 excluded.

162 Search results from each database will be combined and duplicates will be
163 removed before the screening. References will be aggregated into a reference manager
164 tool (EndNote Web) [21]. Additional papers will be identified by searching the reference
165 lists of relevant articles and their citation metrics.

166 Outcomes and Measures of effect

167 The primary outcome will be all-cause mortality whereas secondary outcomes
168 were (1) composite cardiovascular or (2) cardiac endpoints, defined as:

169 (1) composite CV endpoints, including any combination of CV mortality, coronary
170 heart disease (CHD) events (myocardial infarction-MI, unstable angina, angina/ischemia
171 requiring emergent hospitalization or revascularization), HF hospitalization, new-onset
172 atrial fibrillation (AF), life-threatening arrhythmia, recorded automatic implantable
173 cardioverter-defibrillator (AICD) shocks, stroke, transit ischemic attack or peripheral
174 arterial disease with arterial revascularization procedure;

175 (2) composite cardiac endpoints, including any combination of CV mortality, CHD
176 events (MI, unstable angina, angina/ischemia requiring emergent hospitalization or
177 revascularization), HF hospitalization, new-onset AF, life-threatening arrhythmia,
178 recorded AICD shocks.

179 Tertiary outcomes will be any individual secondary endpoint not included in the
180 composite cardiac or CV endpoint.

181 Due to the characteristics of Doppler and CMR (Cardiovascular magnetic
182 resonance imaging) -based strain, we only will be included studies that calculated strain
183 by STE. A draft for the Eligibility and Data Extraction Form to be used is detailed in
184 Supplementary file 3.

185 We will provide a narrative synthesis of the findings from the included studies.
186 We will provide summaries of intervention effects for each study by calculating risk ratios
187 (for dichotomous outcomes) or standardized mean differences (for continuous
188 outcomes) from the data presented in the published studies or obtained from study
189 authors.

190 Study reviews and appraisals

191 Initial title and abstract screening will be performed using Rayyan software [22]
192 and full texts of selected articles will be retrieved and double screened for eligibility and
193 data extraction by six researchers working independently (AGSM, BLSGM, EPB, GCD,
194 JVD, MADS). Discrepancies will be resolved through consensus or the opinion of a third
195 review author (JJVT or RTPO) will be sought. For multiple study publications from the
196 same patient cohort, we will choose the study with the largest number of cases, or which
197 one that reported the results separately according to the CKD stage, once there are
198 many studies whose results of patients with early-to-moderate CKD stage are reported
199 together with ESRD patients, which makes it impossible to correctly analyze these
200 subgroups. For studies that presented different outcomes, we will be extracted outcomes
201 from both publications.

202 Reasons for study exclusion will be documented. Data extraction will be validated
203 by methodological and clinical experts (IGD, JJVT and RTPO, SSY, respectively). Also,
204 information reported in the grey literature will be sought. We will report our search terms
205 as an appendix to published studies.

206 Data extraction

207 The following data will be extracted: (1) citation details (title, type, and year of
208 publication); (2) study details (name, region, and design of the study, sample size); (3)
209 participant details including demographics (age, sex, ethnicity, and follow-up duration),
210 clinical (hypertension, diabetes mellitus-DM, dyslipidemia, smoking status, and known

211 CVD), and laboratory variables; (4) exposure details (hardware and the software used
212 for the acquisition and analysis as well as details regarding the measured LV strain); (5)
213 details of outcomes, including how these were ascertained; (6) statistical methods used,
214 as well as statistics related to the association of interest, and (7) information related to
215 adjustment for potential confounders.

216 If samples are reported at multiple time points within a study, then each one will
217 be considered individually. If these data are not available, we will extract the association
218 measures that were used. If study data, critical to our proposed analysis, is unclear or
219 absent, the relevant authors will be contacted for clarification.

220 Quality assessment, data synthesis, and exploration of heterogeneity

221 A modified version of the NOS (Newcastle-Ottawa Quality Assessment Scale of
222 cohort studies) will be used to assess the quality of included papers (Supplementary file
223 4) [23]. Statistical analyses will be performed using Review Manager 5.4 software. This
224 information will be summarized graphically in the final review document. Studies will not
225 be excluded from the main meta-analysis based on the risk of bias.

226 The degree of heterogeneity will be assessed using the Higgins Thompson I^2 test
227 [24] and Cochran's Q test [25]. If possible, according to the included studies, a
228 quantitative synthesis using random-effect meta-analysis will be used to pool the results
229 of the association of interest. For presenting the results, we will likely use the HR (95%CI)
230 as an effect estimate, and will present the data graphically in forest plots. If data allow,
231 we will perform meta-regression to explore potential sources of between-study
232 heterogeneity: (1) study quality, (2) variation in exposure measurement (a type of strain-
233 longitudinal, circumferential or radial strain), and (3) variation in a CV and cardiac
234 outcomes definition. Possible publication bias will be assessed using a Funnel plot [26].
235 We will assess evidence of publication bias using Egger's weighted regression method
236 for continuous outcomes, and Begg's rank correlation test for dichotomous outcomes.
237 Statistical analysis will be carried out in the Review Manager 5.4 software. An adaptation
238 of the GRADE framework for prognostic studies will be employed to judge the quality of
239 evidence for each outcome reported in this systematic review [27].

240 Discussion

241 This systematic review will summarize current evidence about STE-derived
242 measures in the ESRD patients. Studies reported associations between STE-derived
243 measures and all-cause and cardiovascular mortality and CV outcomes, but, is not fully
244 understood the potential prognostic value of this diagnostic tool in ESRD patients.
245 Evidence concerning measures (circumferential strain, radial strain) or 3D STE-derived
246 indices will also be investigated. Therefore, this systematic review will also be displayed
247 important knowledge gaps in the current literature regarding the possible utility of
248 myocardial deformation indices in ESRD patients.

249 The mechanisms of decreased LV function in CKD patients are complex and not
250 thoroughly understood [28] but CKD patients undergo a progressive change in
251 myocardial composition and function due to pressure and volume overload, ischemia
252 and CKD-related biochemical abnormalities.

253 The increased risk for cardiovascular morbidity and mortality might be caused by
254 uremic cardiomyopathy (UC), a common complication in patients with ESRD that is
255 characterized by cardiac fibrosis, capillary rarefaction, left ventricular hypertrophy, and
256 both systolic and diastolic dysfunction [12-14, 29]. Therefore, early detection of UC by
257 STE in patients with ESRD might identify patients at risk.

258 Ejection fraction (EF) measured from conventional echocardiogram is the gold
259 standard for assessment of LV systolic function. However, EF has important technical
260 limitations including load and geometry dependency and lacks sensitivity to detect subtle
261 LV dysfunction [30].

262 Global longitudinal strain (GLS) is an emerging technique for measuring more
263 subtle disturbances in LV systolic function. The two-dimensional strain method uses
264 frame-by-frame tracking of naturally occurring acoustic reflections (speckles) that move
265 with cardiac segments during the cardiac cycle; allowing measurement and
266 characterization of regional and global systolic function. Less negative longitudinal strain
267 (peak global) was associated with increased cardiovascular mortality. A more positive,
268 and hence more abnormal GLS, was also associated with cardiac death [31-33].

269 Although radial, circumferential, and longitudinal fibers are predominantly in
270 different layers of the myocardium, there is evidence of reduced myocardial deformation
271 in all these orientations when we compared ESRD patient cohort to healthy persons [29].
272 As heart muscle is incompressible, strain parameters are interrelated in three
273 dimensions, thus, by the time the chamber contracts and shortens in systole
274 (circumferential and longitudinal strain), the wall thickens (radial strain) [34].

275 This systematic review will provide essential data regarding STE-derived
276 measures as prognostic indicators of mortality and CV events in End-stage renal disease
277 patients. The clinical implications of this work relate to the current status of diagnosis
278 and treatment of heart disease in patients receiving dialysis.

279 Availability of data and materials

280 The datasets generated and/or analyzed during the current study are available
281 from the corresponding author on reasonable request.

282 **List of Abbreviations**

283 AF: Atrial fibrillation

284 AICD: Automatic implantable cardioverter defibrillator

285 CHD: Coronary heart disease

286 CMR: Cardiovascular magnetic resonance imaging

287 CRS: Cardiorenal syndrome

288 CVD: Cardiovascular disease

289 DM: Diabetes mellitus

290 EF: Ejection fraction

291 ESRD: End-Stage Renal Disease

292 GLS: Global Longitudinal Strain

293 HD: Hemodialysis

294 HF: Heart failure

295 LILACS: Latin American and Caribbean Literature in Health Sciences

296 LV: Left ventricular

297 MI: Myocardial infarction

298 NOS: Newcastle-Ottawa Quality Assessment Scale of cohort studies

299 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
300 Protocols

301 PROSPERO: International registry of systematic reviews

302 RRT: Renal replacement therapy

303 STE: Speckle-tracking echocardiography

304 UC: Uremic cardiomyopathy

305 **References**

306 [1]. USRDS. Annual Data Report 2015: International Comparisons, 2015. Available at:
307 https://www.usrds.org/2015/download/vol2_13_International_15.pdf.

308 [2]. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC).
309 Kidney Disease Statistics for the United States 2012. Available at:
310 [https://www.niddk.nih.gov/health-information/health-statistics/Pages/kidney-disease-](https://www.niddk.nih.gov/health-information/health-statistics/Pages/kidney-disease-statistics-united-states.aspx)
311 [statistics-united-states.aspx](https://www.niddk.nih.gov/health-information/health-statistics/Pages/kidney-disease-statistics-united-states.aspx).

312 [3]. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease
313 in chronic renal disease. *Am J Kidney Dis* 1998; 32(Suppl 3): S112–S119.

314 [4]. US Renal Data System. 2016 Annual Data Report: Epidemiology of Kidney Disease
315 in the United States. Bethesda, MD: National Institutes of Health, National Institute of
316 Diabetes and Digestive and Kidney Diseases; 2016. Available at: <https://www.usrds.org/>.

317 [5]. Ahmadmehrabi S, Wilson Tang WH. Hemodialysis-induced cardiovascular disease.
318 *Seminars in Dialysis*. 2018;31:258–267.

319 [6]. Foley RN, Parfrey PS, Harnett JD et al., Clinical and echocardiographic disease in
320 patients starting end-stage renal disease therapy, *Kidney International*, 1995. vol. 47,
321 no. 1, pp. 186–192.

322 [7]. Severino P, Maestrini V, Mariani MV, Birtolo LI, Scarpati R, Mancone M, Fedele F.
323 Structural and myocardial dysfunction in heart failure beyond ejection fraction. *Heart*
324 *failure reviews*, 2020. 25(1), 9-17.

325 [8]. Ibrahim MK, Kamal OMM, Hassan MS, Khalifa MMM. Interdialytic Weight Gain and
326 Its Relation to Outcome among Patients on Maintenance Hemodialysis. *QJM: An*
327 *International Journal of Medicine*, 2020. 113(Supplement_1), hcaa052-020.

328 [9]. Mele D, Andrade A, Bettencourt P, Moura B, Pestelli G, Ferrari R. From left
329 ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in
330 evaluating patients with heart failure. *Heart failure reviews*, 2020. 25(2), 217-230.

331 [10]. Ciavarella GM, Altieri S, Limite LR, Russo D, Luciani M, De Biase L, Volpe M.
332 Longitudinal changes of left and right cardiac structure and function in patients with end-
333 stage renal disease on replacement therapy. *European journal of internal medicine*,
334 S0953-6205.

335 [11]. Liu YW, Tsai WC, Su CT et al. Evidence of left ventricular systolic dysfunction
336 detected by automated function imaging in patients with heart failure and preserved left
337 ventricular ejection fraction. *J Card Fail*, 2009. 15:782–789

338 [12]. Lu DY, Ventoulis I, Liu H, Kudchadkar SM, Greenland GV, Yalcin H, Zimmerman
339 SL. Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic
340 cardiomyopathy. *American heart journal*, 2020. 219, 58-69.

341 [13]. Ishizu T, Seo Y, Kameda Y, Kawamura R, Kimura T, Shimojo N, Aonuma K. Left
342 ventricular strain and transmural distribution of structural remodeling in hypertensive
343 heart disease. *Hypertension*, 2014. 63(3), 500-506.

344 [14]. Sun M, Kang Y, Cheng L, Pan C, Cao X, Yao H, Shu X. Global longitudinal strain is
345 an independent predictor of cardiovascular events in patients with maintenance
346 hemodialysis: a prospective study using three-dimensional speckle tracking

- 347 echocardiography. *The international journal of cardiovascular imaging*, 2016. 32(5), 757-
348 766.
- 349 [15]. Wang H, Liu J, Yao XD et al. Multidirectional myocardial systolic function in
350 hemodialysis patients with preserved left ventricular ejection fraction and different left
351 ventricular geometry. *Nephrol Dial Transplant* 2012; 27: 4422–4429.
- 352 [16]. Liu YW, Su CT, Huang YY, Yang CS, Huang JW, Yang MT, Tsai WC. Left
353 Ventricular Systolic Strain in Chronic Kidney Disease and Hemodialysis Patients.
354 *American Journal of Nephrology*, 2011. 33(1), 84–90.
- 355 [17]. Yotti R, Bermejo J, Benito Y, Sanz-Ruiz R, Ripoll C, Martinez-Legazpi P, et al.
356 Validation of noninvasive indices of global systolic function in patients with normal and
357 abnormal loading conditions: a simultaneous echocardiography pressure-volume
358 catheterization study. *Circ Cardiovasc Imaging* 2014; 7:164-72.
- 359 [18]. Floege J, Gillespie IA, Kronenberg F, Anker SD, Gioni I, Richards S, et al.
360 Development and validation of a predictive mortality risk score from a European
361 hemodialysis cohort. *Kidney Int* 2015; 87:996-1008.
- 362 [19]. Zhang T, Li J & Cao S. Prognostic value of left ventricular global longitudinal strain
363 in chronic kidney disease patients: a systematic review and meta-analysis. *International*
364 *Urology and Nephrology*. 2020.
- 365 [20]. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P,
366 Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis
367 Protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015; 4(1):1. doi: 10.1186/2046-4053-
368 4-1.
- 369 [21]. ENDNOTE WEB McKinney, A. EndNote Web: Web-Based Bibliographic
370 Management. *Journal of electronic resources in medical libraries*, 2013 10(4), 185-192.
- 371 [22]. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile
372 app for systematic reviews. *Systematic reviews*, 2016. 5(1), 210.
- 373 [23]. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-
374 Ottawa quality assessment scale cohort studies. Available on: [http://www.ohri.](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
375 [ca/programs/clinical_epidemiology/oxford. asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- 376 [24]. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-
377 analyses. *BMJ* 2003; 327:557–60. 45. Higgins JP, Thompson SG. Quantifying
378 heterogeneity in a metaanalysis. *Stat Med* 2002; 21:1539–58.
- 379 [25]. Cochran WG. The comparison of percentages in matched samples. *Biometrika*,
380 1950. 37(3/4), 256-266.
- 381 [26]. Sterne, JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Tetzlaff J.
382 Recommendations for examining and interpreting funnel plot asymmetry in meta-
383 analyses of randomised controlled trials. *BMJ*, 2011 343.
- 384 [27]. Hugué A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al.
385 Judging the quality of evidence in reviews of prognostic factor research: adapting the
386 GRADE framework. *Syst Rev*. 2013; 2:71. doi:10.1186/2046-4053-2-71.
- 387 [28]. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in
388 estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol*.
389 2009; 20:2617–2624.
- 390 [29]. Kramann R, Erpenbeck J, Schneider RK, Röhl A B, Hein M, Brandenburg VM,
391 Becker M. Speckle tracking echocardiography detects uremic cardiomyopathy early and
392 predicts cardiovascular mortality in ESRD. *Journal of the American Society of*
393 *Nephrology*, 2014 25(10), 2351-2365.

- 394 [30]. Marwick TH. Methods used for the assessment of LV systolic function: common
395 currency or tower of Babel? *Heart* 2013; 99: 1078–1086.
- 396 [31]. Patel J, Rikhi R, Hussain M, Ayoub C, Klein A, Collier P, Moudgil R. Global
397 longitudinal strain is a better metric than left ventricular ejection fraction: lessons learned
398 from cancer therapeutic-related cardiac dysfunction. *Current Opinion in Cardiology*,
399 2020. 35(2), 170-177.
- 400 [32]. Al Saikhan L, Park C, Hardy R, Hughes A. Prognostic implications of left ventricular
401 strain by speckle-tracking echocardiography in the general population: a meta-analysis.
402 *Vasc Health Risk Manag*. 2019; 15:229-251.
- 403 [33]. Miguel LSM, Villarraga HR, Abduch MCD, Lima MF, Cruz CBBV, Sbano JCN et al.
404 Global Longitudinal Strain or Left Ventricular Twist and Torsion? Which Correlates Best
405 with Ejection Fraction?. *Arq. Bras. Cardiol*. 2017 July; 109(1): 23-29.
- 406 [34]. Abduch MCD, Mesquita AA, Mathias Jr W, Vieira MLC. Cardiac Mechanics
407 Evaluated by Speckle Tracking Echocardiography. *Arq. Bras. Cardiol*. [Internet]. 2014
408 Apr [cited 2020 Aug 09] ; 102(4): 403-412.

409

410 **Declarations**

411 Ethics approval and consent to participate: Not applicable.

412 Consent for publication: Not applicable.

413 Availability of data and materials: All data generated or analyzed during this study are
414 included in this published article [and its supplementary information files].

415 Competing interests: The authors declare that they have no competing interests.

416 Funding: None.

417 Authors' contributions: BLSGM has prepared this manuscript with clinical and
418 methodological support from RTPO and JJVT, respectively. This manuscript has been
419 reviewed by AGSM, EPB, GCD, JVD, MADS, IGD, SSY, RTPO and JJVT and edited by
420 IGD, SSY, RTPO and JJVT. BLSGM is the corresponding author and has registered the
421 protocol with the PROSPERO database. All authors agreed to be accountable for all
422 aspects of this work and approved the final submission.

423 Authors' information:

424 Affiliations

425 Clinical Analysis and Biomedicine Department, State University of Maringa, PR, BR.

426 JJVT.

427 Clinical Analysis Department, Federal University of Santa Catarina (UFSC),
428 Florianópolis, SC, BR.

429 IGD.

430 Graduate Program in Biosciences and Pathophysiology (PBF-UEM), State University of
431 Maringa, PR, BR.

432 BLSGM, JJVT, RPTO.

433 Hypertension Academic League, Regional University Hospital, State University of
434 Maringa, PR, BR.

435 AGSM, EPB, GCD, JVD, MADS, RTPO.

436 Medicine Department, State University of Maringa, PR, BR.

437 RTPO, SSY.
438 Research Group on Systemic Arterial Hypertension, Arterial Stiffness and Vascular
439 Aging (GPHARV-UEM), Regional University Hospital, State University of Maringa, PR,
440 BR.
441 BLSGM, RTPO, SSY.
442 Uningá, Inga University Center, Maringa, PR, BR.
443 JVD.
444 Corresponding author: Correspondence to Barbara de Moura.
445 Supplementary information
446 Supplementary file 1.
447 PRISMA-P Checklist.
448 Supplementary file 2.
449 Draft Search strategy.
450 Supplementary file 3.
451 Eligibility Form / Data Extraction Form.
452 Supplementary file 4.
453 Modified NOS Risk of Bias assessment.